Hengrui Pharma (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has recently received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for the drug Adebrelimab Injection. The clinical trial will commence shortly.
According to Zhitong Finance, Hengrui Pharma (01276) announced that its subsidiary, Shanghai Shengdi Pharmaceutical Co., Ltd., has recently received the 'Clinical Trial Approval Notice' issued by the National Medical Products Administration for Adebrelimab Injection. The company will soon commence clinical trials.
Adebrelimab Injection is a humanized anti-PD-L1 monoclonal antibody independently developed by the company. It works by specifically binding to the PD-L1 molecule, thereby blocking the PD-1/PD-L1 pathway that leads to tumor immune tolerance and reactivating the immune system's antitumor activity to achieve therapeutic effects on tumors. The company’s Adebrelimab Injection was approved for marketing in 2023, with the approved indication being its use in combination with carboplatin and etoposide as first-line treatment for patients with extensive-stage small cell lung cancer. Similar products abroad include Atezolizumab (trade name: Tecentriq), Avelumab (trade name: Bavencio), and Durvalumab (trade name: Imfinzi), which have been approved for sale in the United States. Among these, Atezolizumab and Durvalumab have already been approved for marketing in China. Multiple similar products have also been approved for marketing within China. According to reports, the global sales revenue of Atezolizumab, Avelumab, and Durvalumab combined amounted to approximately USD 9.648 billion in 2024. To date, the cumulative R&D investment related to Adebrelimab Injection amounts to approximately RMB 1.1514 billion (unaudited).
